Candel Therapeutics To Present Preclinical Results For CAN-3110 In Melanoma At SITC Annual Meeting
Candel Therapeutics To Present Preclinical Results For CAN-3110 In Melanoma At SITC Annual Meeting
Candel Therapeutics將在海豐國際年會上介紹CAN-3110在黑色素瘤中的臨床前結果
- Abstract selected as poster presentation during the Society for Immunotherapy of Cancer (SITC) Annual Meeting shows potent antitumor activity of CAN-3110 in preclinical models of melanoma
- CAN-3110's activity is designed to be conditional to the expression of Nestin in cancer cells and is associated with dual activity for oncolysis and immune activation
- Findings support potential indication expansion for CAN-3110 beyond high-grade glioma into melanoma, another Nestin-expressing solid tumo
- 所選摘要將在癌症免疫治療學會（SITC）年會上作爲海豐國際的CAN-3110在黑色素瘤實驗模型中展示出強勁的抗腫瘤活性的海報展示
- CAN-3110的活性設計爲與癌細胞中Nestin的表達條件有關，與潰瘍和免疫激活的雙重活性相關
- 研究結果支持CAN-3110在高級別膠質瘤以外的領域，如黑色素瘤，進一步擴展適應性，另一種表達Nestin的實體腫瘤
資訊熱榜
更新時間